HIT Consultant – Read More
What You Should Know
- Precision oncology and cancer risk intelligence platform CancerIQ announced a major architectural upgrade to its Epic Systems integrations, introducing a redesigned patient experience via Risk Hub and a consolidated provider application deployed natively inside Epic workflows.
- Built natively on the HL7 FHIR R4 interoperability standard, the provider integration enables chart-aware risk assessment that automatically pulls existing clinical variables from Epic—including family cancer histories, personal diagnoses, prior breast biopsies, breast density reports, lab findings, and medication regimens—to eliminate duplicative patient data entry.
- Embeds clinical decision-support guidelines directly into Epic to identify patient eligibility across hereditary risk screening, germline and somatic genetic testing, biomarker panels, minimal residual disease (MRD) monitoring, and multi-cancer early detection (MCED) blood tests without requiring clinicians to switch windows or log into external third-party portals.
Chart-Aware Provider Integration Built on FHIR R4
Deployed across more than 60 health systems and 275 clinic locations (reaching roughly 1 in 10 patients nationwide), the upgraded integrations are accessible via Connection Hub on the Epic Showroom.
The upgraded provider integration uses the HL7 FHIR R4 standard to bi-directionally read from and write to Epic, eliminating redundant data entry and keeping clinicians within their native EHR interface:
- Prepopulated Chart Ingestion: Automatically ingests existing chart data—including family cancer histories, personal diagnoses, prior biopsies, breast density markers, medication lists, and past lab/genomic results—to auto-populate risk assessment models before the clinician opens the chart.
- Embedded Guideline Engine: Evaluates ingested patient data against evidence-based clinical guidelines to determine eligibility for:
- Hereditary cancer risk assessment and genetic testing (e.g., BRCA1/2, Lynch syndrome).
- Targeted biomarker testing.
- Health-system-specific Minimal Residual Disease (MRD) surveillance monitoring.
- Emerging Multi-Cancer Early Detection (MCED) blood-based screening programs.
- Unified In-EHR Workflows: Clinicians can review and refine pedigrees, order indicated genetic/biomarker tests through standard EHR computerized provider order entry (CPOE), and generate personalized care plans (screening intervals, imaging modalities, and specialty referrals) directly within Epic.
- EHR Genomics Module Synergy: Works alongside specialized electronic health record tools (such as Epic’s native Genomics module at partner health systems like OSF HealthCare) to convert complex genomic variant reports into structured, actionable clinical surveillance schedules.
Redesigned Patient Experience via “Risk Hub”
Alongside the clinician toolset, CancerIQ updated its patient-facing application, Risk Hub, which can be deployed independently or alongside the EHR provider module:
- Patient Portal Integration: Patients authenticate securely via their health system’s patient portal (e.g., Epic MyChart) and authorize CancerIQ to pull supported EHR health data.
- Reduced Intake Burden: Instead of filling out blank family-history questionnaires from scratch, patients review, confirm, or update pre-populated records.
- Longitudinal Precision Navigation: Provides clear, tailored risk literacy education explaining why specific genetic tests or dense-breast MRIs are indicated, while guiding patients through post-test surveillance intervals and survivorship care plans over time.
“As CancerIQ has expanded to support more of the patient journey, bringing those capabilities directly into Epic was the natural next step,” said Feyi Ayodele, Co-founder and CEO of CancerIQ. “Care teams shouldn’t have to leave Epic to do their best work, and patients should have a clear understanding of their risk, recommended next steps and what comes after. These updates bring providers and patients together, helping everyone stay a step ahead of cancer.”
